Logo iOmx.JPG
iOmx to Present New Pre-Clinical Data on SIK3 Checkpoint Inhibitor OMX-0407 at AACR 2022
07 avr. 2022 04h00 HE | iOmx Therapeutics AG
MARTINSRIED / MUNICH, Germany, April 07, 2022 (GLOBE NEWSWIRE) -- iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint...
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association
18 juin 2019 08h00 HE | Amarantus Bioscience Holdings, Inc.
NEW YORK, NY, June 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...